0001477932-26-001083
SEC filingTHC Therapeutics, Inc. reported no revenue for FY 2024, consistent with FY 2023, as the company remains in the development stage focused on its dHydronator® herb dryer. The company incurred a net loss of $812K for FY 2024, a significant increase from the $387K net loss in FY 2023. This deterioration was driven by a $48K increase in operating loss to $542K and a $376K unfavorable swing in other income/expense to a $270K loss, primarily due to a $125K loss on derivative liability and increased interest expense. The company's financial condition is precarious, with only $35 in cash, total assets of $11K, and a substantial working capital deficit of $3.7M against total liabilities of $3.8M. Management's report includes a going concern qualification, citing the accumulated deficit of $39.2M and insufficient cash to support operations for the next twelve months without additional financing.
THC Therapeutics, Inc. reported no revenue for the fiscal years ended July 31, 2024 and 2023, as the company is in the development stage with no commercial sales. The net loss for FY 2024 was $811,562, a significant increase of 110% from the $387,036 net loss in FY 2023. This deterioration was driven by a combination of factors: operating loss increased by $48,063 (10%) to $541,975, and other income/expense shifted unfavorably by $376,463 to a loss of $269,587, compared to a gain of $106,876 in the prior year. The increase in operating expenses to $541,975 was primarily due to higher professional fees ($266,637, up 13%) and general & administrative expenses ($240,795, up 242%), partially offset by a decrease in salaries and wages ($34,543, down 82%). The negative swing in other income/expense was largely attributable to a $125,444 loss on change in derivative liability (versus a $184,143 gain in FY 2023) and increased interest expense of $144,143 (up 81%).
The company generated zero revenue in both FY 2024 and FY 2023. Management states in the filing that "We did not earn any revenue during the fiscal years ending July 31, 2024 and 2023" and "We do not anticipate earning significant revenues until such time that we have fully developed our operational strategy and launched sales of our herb dryer product." The company's business is focused on developing the dHydronator® sanitizing herb dryer for the cannabis and wellness industries, but it has not yet commenced commercial operations or generated any product sales. No segment revenue breakdown is provided as the company operates as a single reportable segment.
With zero revenue, gross profit was $0 and gross margin is not calculable. The operating loss margin, calculated as operating loss relative to revenue, is not meaningful given the absence of revenue. The company's cost structure is dominated by operating expenses totaling $541,975, which consist entirely of professional fees ($266,637), general and administrative expenses ($240,795), and salaries and wages ($34,543). These expenses represent the costs of maintaining the company as a development-stage entity, including legal, accounting, and compliance costs, as well as stock-based compensation. The increase in operating loss from $493,912 in FY 2023 to $541,975 in FY 2024 reflects the company's ongoing investment in development activities despite having no revenue stream.
The company's liquidity position is extremely constrained. As of July 31, 2024, cash was only $35, with total current assets of $35 and total assets of $10,648 (primarily intangible assets of $11,000). This is offset by total current liabilities of $3,712,203, resulting in a working capital deficit of $3,712,168. Total liabilities stand at $3,712,203, consisting mainly of accounts payable and accrued liabilities ($1.3M), related-party payables ($1.0M), convertible notes payable ($707K), and derivative liability ($615K). Stockholders' deficit is $3,701,555, including an accumulated deficit of $39.2M. Cash flow from operations was negative $183,273 for FY 2024, an increase from negative $85,432 in FY 2023. This was partially offset by $183,298 in financing cash flows, primarily from related-party advances ($86K) and preferred stock sales ($98K). The company has no free cash flow (defined as operating cash flow minus capital expenditures) as it had no investing activities.
Management has expressed substantial doubt about the company's ability to continue as a going concern, citing the accumulated deficit of approximately $39.2 million, lack of revenue, and insufficient cash to support operations for the next twelve months. The company estimates it will need approximately $3,810,000 over the next 12 months to implement its plan of operations, which includes finalizing product design, manufacturing pre-production units, hiring personnel, and conducting market research. Management intends to seek funding through equity offerings, debt financing, or other sources, but acknowledges "there can be no assurance that we will be successful in raising additional funding." Key risk factors include dependence on raising capital, regulatory uncertainties in the cannabis industry, intellectual property protection, competition, and reliance on key personnel. The company's strategic focus remains on developing and commercializing the dHydronator® herb dryer while seeking acquisition opportunities in the cannabis industry.